Huan Jia-Ming, Ma Xi-Ting, Li Si-Yi, Hu Dong-Qing, Chen Hao-Yu, Wang Yi-Min, Su Xiao-Yi, Su Wen-Ge, Wang Yi-Fei
School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR,China.
Front Pharmacol. 2023 Apr 4;14:1126972. doi: 10.3389/fphar.2023.1126972. eCollection 2023.
Hypertensive nephropathy (HN) is a common complication of hypertension. Traditional Chinese medicine has long been used in the clinical treatment of Hypertensive nephropathy. However, botanical drug prescriptions have not been summarized. The purpose of this study is to develop a prescription for improving hypertensive nephropathy, explore the evidence related to clinical application of the prescription, and verify its molecular mechanism of action. In this study, based on the electronic medical record data on Hypertensive nephropathy, the core botanical drugs and patients' symptoms were mined using the hierarchical network extraction and fast unfolding algorithm, and the protein interaction network between botanical drugs and Hypertensive nephropathy was established. The K-nearest neighbors (KNN) model was used to analyze the clinical and biological characteristics of botanical drug compounds to determine the effective compounds. Hierarchical clustering was used to screen for effective botanical drugs. The clinical efficacy of botanical drugs was verified by a retrospective cohort. Animal experiments were performed at the target and pathway levels to analyze the mechanism. A total of 14 botanical drugs and five symptom communities were obtained from real-world clinical data. In total, 76 effective compounds were obtained using the K-nearest neighbors model, and seven botanical drugs were identified as Gao Shen Formula by hierarchical clustering. Compared with the classical model, the Area under the curve (AUC) value of the K-nearest neighbors model was the best; retrospective cohort verification showed that Gao Shen Formula reduced serum creatinine levels and Chronic kidney disease (CKD) stage [OR = 2.561, 95% CI (1.025-6.406), < 0.05]. With respect to target and pathway enrichment, Gao Shen Formula acts on inflammatory factors such as TNF-α, IL-1β, and IL-6 and regulates the NF-κB signaling pathway and downstream glucose and lipid metabolic pathways. In the retrospective cohort, we observed that the clinical application of Gao Shen Formula alleviates the decrease in renal function in patients with hypertensive nephropathy. It is speculated that Gao Shen Formula acts by reducing inflammatory reactions, inhibiting renal damage caused by excessive activation of the renin-angiotensin-aldosterone system, and regulating energy metabolism.
高血压肾病(HN)是高血压常见的并发症。中医长期应用于高血压肾病的临床治疗。然而,植物药方剂尚未得到总结。本研究旨在研发一种改善高血压肾病的方剂,探索该方剂临床应用的相关证据,并验证其分子作用机制。在本研究中,基于高血压肾病的电子病历数据,采用层次网络提取和快速展开算法挖掘核心植物药和患者症状,建立植物药与高血压肾病之间的蛋白质相互作用网络。利用K近邻(KNN)模型分析植物药化合物的临床和生物学特征以确定有效化合物。采用层次聚类筛选有效植物药。通过回顾性队列研究验证植物药的临床疗效。在靶点和通路水平进行动物实验以分析作用机制。从真实世界临床数据中总共获得14味植物药和5个症状群落。使用K近邻模型共获得76种有效化合物,通过层次聚类确定7味植物药为高参方。与经典模型相比,K近邻模型的曲线下面积(AUC)值最佳;回顾性队列验证表明,高参方降低血清肌酐水平和慢性肾脏病(CKD)分期[比值比(OR)=2.561,95%置信区间(CI)(1.025 - 6.406),P<0.05]。在靶点和通路富集方面,高参方作用于肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)和白细胞介素-6(IL-6)等炎症因子,调节核因子-κB(NF-κB)信号通路及下游糖脂代谢通路。在回顾性队列中,我们观察到高参方的临床应用减轻了高血压肾病患者肾功能的下降。推测高参方通过减轻炎症反应、抑制肾素-血管紧张素-醛固酮系统过度激活所致的肾损伤以及调节能量代谢发挥作用。